U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06961617) titled 'Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma' on May 06.
Brief Summary: This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
Study Start Date: June 01, 2024
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: LioCyx-M, HBV antigen-specific TCR-redirected T cells
Via intravenous (IV) infusion
Recruitment Status: RECRUITING
Sponsor: Lion TCR Pte. Ltd.
Published by HT Digital Content Services with permission from Hea...